Antidiabetic, antioxidant and antihyperlipidemic status of Heliotropium zeylanicum extract on streptozotocin-induced diabetes in rats.
The potential role of the methanolic extract of Heliotropium zeylanicum (BURM.F) LAMK (MEHZ) in the treatment of diabetes along with its antioxidant and antihyperlipidemic effects was studied in streptozotocin-induced diabetic rats. Oral administration of (MEHZ) 150 and 300 mg/kg/d for 14 d significantly decreased the blood glucose level and considerably increased the body weight, food intake, and liquid intake of diabetic-induced rats. MEHZ significantly decreased thiobarbituric acid reactive substances and significantly increased reduced glutathione, superoxide dismutase and catalase in streptozotocin-induced diabetic rats at the end of 14 d of treatment. The study also investigated the antihyperlipidemic potential of MEHZ. The results show that the active fraction of MEHZ is promising for development of a standardized phytomedicine for the treatment of diabetes mellitus.
Murugesh
Kandasamy
K
Department of Pharmaceutical Technology, Division of Pharmaceutical Chemistry, Jadavpur University, Kolkata, India. sarugesh@yahoo.com
Yeligar
Veerendra
V
Dash
Deepak Kumar
DK
Sengupta
Pinaki
P
Maiti
Bhim Chandra
BC
Maity
Tapan Kumar
TK
D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D028162:Heliotropium / Q000737:chemistry*; D006937:Hypercholesterolemia / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D015228:Hypertriglyceridemia / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008517:Phytotherapy / Q000379:methods; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014044:Tolbutamide / Q000494:pharmacology
D000975:Antioxidants; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010936:Plant Extracts; D017392:Thiobarbituric Acid Reactive Substances; D013311:Streptozocin; D014044:Tolbutamide; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione